TJX Posts Strong Q3 Sales, Joins BellRing Brands, Bullish And Other Big Stocks Moving Higher On Wednesday
U.S. stocks mostly fell, but TJX jumped 10.3% on strong sales and higher guidance; BellRing and other stocks also posted notable gains.
Last updated: 2026-11-19 02:28:00. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Avita Medical, Inc. (RCEL) operates in the SURGICAL & MEDICAL INSTRUMENTS & APPARATUS sector and is listed on NASDAQ. The stock is currently priced at $16.79, with a market capitalization of $482.29M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $3.22 to $18.43. This page covers its latest market performance, valuation, price trends and company information.
$482.29M | |
$15.87 | |
$17.68 | |
$15.44 | |
$15.77 | |
674.30K | |
412.09K | |
-- | |
$18.43 | |
$3.22 | |
-- | |
2026-09-30 |
Avita Medical, Inc. (RCEL) last closed at $16.79 as of 2026-11-19 00:41:00, up 6.53% ($1.03) from the previous close of $15.77.
During the latest regular trading session, RCEL traded between $15.44 and $17.68, with a volume of 674.30K shares. The closing price was near the middle and near the upper end of its 52-week range.
Over the past seven days, Avita Medical, Inc. (RCEL) moved from $17.12 to $16.79, representing a decline of 1.96% ($0.34).
The stock traded between $14.74 and $18.43 during the period. The latest price is near the middle of the 7-day range, indicating moderate downward.
The average daily volume was 672.68 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 89.2%
RCEL is currently trading at $16.79, placing it 89.2% of the way from its 52-week low of $3.22 to its 52-week high of $18.43. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Avita is largely a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently used in most of the 140 US burn centers. Despite having product approval in Australia, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region, although international sales, particularly in Japan, are growing. Avita is domiciled, and has its primary listing, in the US.
| Industry | SURGICAL & MEDICAL INSTRUMENTS & APPARATUS |
| Employees | 226 |
| Exchange | NASDAQ |
| Company Website |
Latest news related to Avita Medical, Inc. and RCEL stock.
U.S. stocks mostly fell, but TJX jumped 10.3% on strong sales and higher guidance; BellRing and other stocks also posted notable gains.
Six-month follow-up showed continued wound healing and improving scar scores, with no Cohealyx® related adverse events Tissue samples collected immediately before skin grafting showed matrix integration of Cohealyx and
TD Cowen analyst Joshua Jennings maintains AVITA Medical (NASDAQ:RCEL) with a Buy and raises the price target from $20 to $22.
Avita Medical Inc. (RCEL) received an upgrade to Zacks Rank #2 (Buy) based on upward trends in earnings estimates. The upgrade reflects improving business fundamentals and positions the stock in the top 20% of Zacks-covered stocks, suggesting potential for near-term price appreciation driven by institutional investor buying pressure.
Eligible investors can buy real shares of Avita Medical, Inc. (RCEL) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to RCEL, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between RCEL shares and USD.
RCEL Shares to USD
1.00 RCEL shares = 16.785 USD
Calculations are estimates based on the latest available price and are for reference only.